Overview
PARP (poly ADP ribose polymerase) inhibitors are a class of drugs that have an anti-tumor activity. It has been found that these new drugs can extend the life expectancy of patients who suffer from cancer, Parkinson’s disease, and multiple sclerosis. They also increase the patient’s quality of life, and at the same time, decrease the burden of paying off the outstanding medical bills. PARP inhibitors block a chemical process in cancer cells known as glycosylation. Glycosylation is where the sugar is chemically attached to a protein. This causes a specific genetic reaction in cancer cells.
Get Sample Report with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-sample/3762
Drivers
Growing prevalence of ovarian cancer among women in parallel to the broadening reimbursement policies by the government is expected to augment growth of the PARP inhibitor biomarkers market during the forecast period.
Moreover, rising R&D efforts to develop RNA repair and damage control drugs are expected to boost growth of the PARP inhibitor biomarkers market over the forecast period.
The Epitome of the COVID-19 Debacle
The emergence of the COVID-19 virus was a major hindrance for the global PARP inhibitor biomarkers market in the second and third quarter of 2020. The risk of virus transmission incited the patients as well as healthcare professionals to avoid physical contacts, unless for COVID-infected patients. As a result, the number of appointments witnessed a sharp decline at the healthcare centers. Contrarily, the market participants were able to sustain through the crisis with the rapid adoption of EMRs (electronic medical records) and telehealth services.
Competitive Landscape
Major companies contributing to the global PARP inhibitor biomarkers market include Invitae Corporation, Invitae Corporation, xBPS Bioscience, Inc., NeoGenomics Laboratories, and NeoGenomics Laboratories.
Get PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/3762
Key Takeaways
The PARP inhibitor biomarkers market is anticipated to grow at a CAGR of XX % during the forecast period owing to the rising occurrences of ovarian and breast cancer among women and increasing therapeutic approvals. For instance, in April 2020, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline’s Zejula (niraparib), a PARP inhibitor developed for the treatment of women suffering from advanced ovarian cancer.
In the territorial breakdown, the North American region is projected to hold a commanding position in the global PARP inhibitor biomarkers market on the heels of a rising breast cancer patient pool and increased R&D activities.
Regarding the same, Asia Pacific is another region of interest for the PARP inhibitor biomarkers market on account of growing awareness over breast cancer in rural areas and increasing government support.
Reasons to Purchase this Report
• Current and future of global PARP Inhibitor Biomarkers market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
https://www.coherentmarketinsights.com/promo/buynow/3762
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product & Services
- Market Snippet, By Application
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Mergers and Acquisitions
- PEST Analysis
- HRD Profiling
- Product Mapping
- Recent Developments
- Epidemiology
- Regulatory Scenario
- Comparative Analysis of Biomarkers, by Type
- HRR Testing Potentials
- HRR Related Genes and Lifetime Risk of Cancers
- Trials Combining PARP Inhibitors With Immune Checkpoint Inhibitors
- Impact of HRR Testing On BRCA Market
- Market Dynamics
- Global PARP Inhibitor Biomarkers Market, By Product & Services, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Product Type
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Kits
- Assays
- Services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- BRCA 1 & 2 Testing
- HRD Testing
- HRR Testing
- Others
- Introduction
- Global PARP Inhibitor Biomarkers Market, By Application, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Ovarian Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Others (Prostate, Pancreatic, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global PARP Inhibitor Biomarkers Market, By Region, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2027
- North America
- Market Size and Forecast, By Product & Services, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Product & Services, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Product & Services, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product & Services, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Product & Services, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product & Services, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Myriad Genetics, Inc.*
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Invitae Corporation
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- NeoGenomics Laboratories, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- BPS Bioscience, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Myriad Genetics, Inc.*
- Analyst Views
- Section
- References
- Research Methodology
- About Us and Sales Contact
Inquire more about this report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/3762
Our analysts are experts in this field with years of experience. We at Coherent Market Insights maintain the highest level of accuracy and transparency in the report. The primary and secondary resources used in the report are taken from reliable and high authority sources to deliver 100% accurate and trusted data.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837